13F filer · CIK 1674712
Vivo Capital, LLC
Palo Alto, CA · filing since Q1 2016 · last filing Aug 14, 2026
Reported value
$1.1B
$-107.9M vs prior
Positions
47
New / sold out
7 / 6
Added / reduced
6 / 8
Turnover
13.6%
buys $155.7M · sells $353.8M
Top-10 weight
52.4%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | Tenax Therapeutics Inc | +2,291,667 | +1100.0% | +$33.3M |
| Added | Arrivent BioPharma Inc | +796,181 | +89.9% | +$27.7M |
| Added | Abivax SA - ADR | +175,360 | +73.2% | +$23.4M |
| New | Achieve Life Sciences Inc. | +2,751,032 | – | +$18.0M |
| New | Editas Medicine Inc | +3,555,250 | – | +$11.5M |
| New | Odyssey Therapeutics Inc | +575,000 | – | +$10.8M |
| New | Aura Biosciences Inc | +1,166,667 | – | +$8.3M |
| Added | Moonlake Immunotherapeutics | +400,000 | +40.0% | +$7.8M |
| New | Avalo Therapeutics Inc | +275,000 | – | +$5.1M |
| Added | Alto Neuroscience Inc | +173,307 | +16.7% | +$4.6M |
3 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | Erasca Inc | -8,024,068 | -66.0% | $-147.0M |
| Sold out | Terns Pharmaceuticals Inc | -1,334,418 | -100.0% | $-70.4M |
| Reduced | Tango Therapeutics Inc | -775,011 | -36.0% | $-24.2M |
| Reduced | Praxis Precision Medicines | -67,779 | -20.0% | $-22.7M |
| Sold out | Veradermics Inc | -300,000 | -100.0% | $-18.9M |
| Sold out | Cogent Biosciences Inc | -422,300 | -100.0% | $-16.3M |
| Reduced | SAB Biotherapeutics Inc | -4,120,091 | -36.1% | $-16.1M |
| Reduced | DBV Technologies SA | -822,811 | -30.8% | $-13.5M |
| Sold out | Soleno Therapeutics Inc | -294,909 | -100.0% | $-9.9M |
| Reduced | Unicycive Therapeutics | -1,239,916 | -69.3% | $-5.8M |
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Trevi Therapeutics IncCOMMON | 5,094,668 | $95.0M | 8.68% |
| 2 | Praxis Precision MedicinesCOMMON | 271,116 | $90.8M | 8.29% |
| 3 | Erasca IncCOMMON | 4,127,412 | $75.6M | 6.90% |
| 4 | Arrivent BioPharma IncCOMMON | 1,682,097 | $58.4M | 5.34% |
| 5 | Abivax SA - ADRSPONSORED ADS | 414,899 | $55.3M | 5.05% |
| 6 | Tango Therapeutics IncCOMMON | 1,379,769 | $43.1M | 3.94% |
| 7 | Corvus Pharmaceuticals IncCOMMON | 2,805,816 | $41.9M | 3.83% |
| 8 | Bright Minds Biosciences IncCOMMON | 557,172 | $39.1M | 3.57% |
| 9 | Sinovac Biotech Ltd.SHS | 5,903,000 | $38.2M | 3.49% |
| 10 | Tenax Therapeutics IncCOMMON | 2,500,000 | $36.4M | 3.32% |
37 more rows. Subscribe for $29/month to see every row, download the data and use the API.